Never worked. Never will. Why doesn't management talk to the lab people?
Alzheimer’s therapy flops in phase III clinical trial
Swiss pharmaceutical giant Roche announced today it is ending a phase III clinical trial for the experimental drug gantenerumab, a monoclonal antibody therapy, because the drug has failed to actually help prevent Alzheimer’s disease, Bloomberg reports. Alzheimer’s is thought to be caused, at least in part, by the buildup of β-amyloid plaques in the brain. Gantenerumab was designed to be administered early in the disease’s progression, before severe symptoms develop. Despite promising early results, the antibodies did not halt the formation of the plaques in any meaningful way, sparking new debate over how to treat the debilitating neurological disorder and whether the plaques are even its primary cause.
Time to get in the corporate jets and get those billions back...
Alzheimer’s therapy flops in phase III clinical trial
Swiss pharmaceutical giant Roche announced today it is ending a phase III clinical trial for the experimental drug gantenerumab, a monoclonal antibody therapy, because the drug has failed to actually help prevent Alzheimer’s disease, Bloomberg reports. Alzheimer’s is thought to be caused, at least in part, by the buildup of β-amyloid plaques in the brain. Gantenerumab was designed to be administered early in the disease’s progression, before severe symptoms develop. Despite promising early results, the antibodies did not halt the formation of the plaques in any meaningful way, sparking new debate over how to treat the debilitating neurological disorder and whether the plaques are even its primary cause.
Time to get in the corporate jets and get those billions back...
Breaking news about antibodies for alzheimers
Aucun commentaire:
Enregistrer un commentaire